Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C9H9Cl2N3O · HCl
CAS Number:
Molecular Weight:
282.55
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI key
DGFYECXYGUIODH-UHFFFAOYSA-N
SMILES string
Cl.NC(=N)NC(=O)Cc1c(Cl)cccc1Cl
InChI
1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
assay
≥98% (HPLC)
color
white
solubility
H2O: soluble 12 mg/mL at 60 °C
originator
Promius
Quality Level
Gene Information
human ... ADRA2A(150), ADRA2B(151), ADRA2C(152)
Looking for similar products? Visit Product Comparison Guide
Application
Guanfacine hydrochloride has been used as an α2A adrenoceptor agonist to test its protective effect on hypobaric hypoxia (HH) and in rat brain to measure blood oxygenation level dependent (BOLD) response.
Biochem/physiol Actions
α-2 noradrenergic receptor agonist.
Guanfacine stimulates the brain postsynaptic α2 adrenergic receptor (AR) and mediates the prefrontal cortical (PFC) neuronal regulation and strengthens their network. Guanfacine improves the density of neuronal dendrites and is useful in treating neuropsychiatric disorders. It modulates the synaptic and cytoskeletal proteins expression in prefrontal cortical (PFC) neurons and may improve hypobaric hypoxia (HH) induced PFC dysfunctions. Guanfacine enhances cognitive function and is recommended for attention deficit hyperactivity disorder (ADHD) therapy.
Features and Benefits
This compound was developed by Promius. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Timothy E Wilens et al.
Journal of the American Academy of Child and Adolescent Psychiatry, 51(1), 74-85 (2011-12-20)
To examine efficacy, tolerability, and safety of guanfacine extended release (GXR; ≤4 mg/d) adjunctive to a long-acting psychostimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years of age with suboptimal, but partial, response
Jean Lachaine et al.
Postgraduate medicine, 124(3), 139-148 (2012-06-14)
To understand attention-deficit/hyperactivity disorder (ADHD) treatment patterns and estimate adherence and persistence in Quebec, Canada. This cross-sectional, retrospective prescription claims analysis used a random sample of 15 838 patients with ADHD from a Quebec database (Régie de l'assurance maladie du
Guanfacine promotes neuronal survival in medial prefrontal cortex under hypobaric hypoxia
Kauser H, et al.
Brain Research, 1636, 152-160 (2016)
Yuanyuan Li et al.
Bioanalysis, 4(12), 1445-1456 (2012-07-17)
Direct analysis of dried blood spot (DBS) samples was investigated using a prototype semi-automated robotic device that allows the direct elution of sample spots from a DBS paper card to an online SPE cartridge. The eluted SPE samples were analyzed
Once-daily treatment of ADHD with guanfacine: patient implications
Strange BC
Neuropsychiatric Disease and Treatment, 4(3), 499-499 (2008)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service